# MB-CART19.1 in Refractory SLE

> **NCT06189157** · PHASE1,PHASE2 · RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 29 (estimated)

## Conditions studied

- SLE - Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** MB-CART19.1

## Key facts

- **NCT ID:** NCT06189157
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-12
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06189157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06189157, "MB-CART19.1 in Refractory SLE". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06189157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*